|
AstraZeneca PLC on Wednesday said its breast cancer drugs capivasertib and camizestrant significantly improved progression-free survival in a phase 3 and 2 trial respectively.
The Cambridge-based pharmaceutical company said capivasertib in combination with hormone therapy drug faslodex, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo in patients with advanced or metastatic breast cancer. The trial met both primary endpoints.
The trial was focused on advanced HR-positive breast cancer.
Susan Galbraith, executive vice president of Oncology research & development at Astra, said the data was "exciting" and shows capivasertib could become a "new first-in-class treatment option".
Meanwhile, camizestrant in a phase 2 trial, showed improved progression free survival rate on people with ER-positive breast cancer. Patients treated with camizestrant had a "significantly improved" survival rate compared to those treated with faslodex.
The results from the trial "underscore the potential for camizestrant to achieve this goal in patients with ER-driven breast cancer and we look forward to advancing our comprehensive Phase 3 clinical programme for camizestrant," said Galbraith.
AstraZeneca shares were 2.4% higher at 9,991.00 pence each in London on Wednesday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
